-
Indonesian court hears 'negligence' complaint against state over fires, haze
-
Germany factory production at highest level for 18 months
-
Rubio in Greece to urge against Western civilisation 'decline'
-
Thailand floods death toll rises to 60 since mid-September
-
Micron workers at Taiwan plant vote in favour of strike
-
US pushes Russia for information on plague reports
-
In 'The Social Reckoning,' Jeremy Allen White takes on Facebook's 'frightening' ambition
-
Myanmar leader lands in Malaysia for migrant return talks
-
Chip industry activists call for South Korea to recognise cancer cases
-
Indian central bank hikes rates for first time since 2023
-
Famine-scarred southern Madagascar braces for El Nino
-
US military on Okinawa face curfew, alcohol ban after murder case
-
How the EU regulates lobbyists
-
Fierce lobbying in EU over 'forever chemicals'
-
I.Coast refuge offers lifelong care for youngsters scorned as 'sorcerers'
-
Dodgers beat Braves and Padres avoid sweep in MLB playoffs
-
Indian central bank hikes rates for first time in more than 3 years
-
Mourning, war and elections as Israel marks October 7
-
Hotel Blacklist Launches New Accommodation Industry Risk Assessment Tool
-
Messi says Argentina retirement is 'saddest day of my career'
-
Bangladesh nuclear plant draws hope -- and worry
-
Oil rises and stocks fall as Hormuz worries flare
-
US beat Canada 1-0 to wrap up four-win international break
-
Pacific presses world for help 'surviving' climate change at pre-COP summit
-
Turkey, Australia's joint COP31 leadership raises doubts
-
Verstappen revival to be put to the test in steamy Singapore
-
For Turkish NGOs, COP31 offers rare space for action
-
US woman who survived botched execution is conscious, speaking: lawyers
-
Sleep, appetite, gene-editing experts contend for Nobel chemistry prize
-
Climate champion Australia digging more coal
-
Nobel Peace Prize haunted by the 'spectre' of Trump
-
Emotion, tears as Messi retires from Argentina national team
-
Africa launches own credit agency in bid for cheaper borrowing
-
Dodgers push Braves to the brink of MLB playoff exit
-
US, China, EU: three paths to regulating AI
-
Crisis-stricken Haiti postpones elections
-
Australia's High Court rules against coal mine in landmark climate case
-
N. Korea's Kim pledges 'invariable support' in Putin birthday letter
-
Australia touts new funds for Pacific infrastructure at Fiji 'pre-COP'
-
OGRD Alliance Advances PLPC Multi-Asset Platform Following APHELAR Milestone, Expanding Licensing and Strategic Capital Frameworks
-
Eva Marie Saint, Oscar winner of Hollywood classics, dies at 102
-
Emotion, tears as Messi prepares for Argentina farewell
-
Australia probes app used in cheap smart glasses over privacy fears
-
Kane eyes Ronaldo record after matching England cap mark
-
England needed to 'move on' from World Cup pain, says Tuchel
-
Spain fight back to beat Croatia, Kane adds to record for England
-
O'Neill to stay at Celtic after period of "reflection"
-
Merino double helps Spain beat Croatia, reach Nations League quarters
-
Kane marks 125th England cap with Wembley Nations League double
-
US stocks hit fresh records as oil stabilizes on rising supplies
US regulator approves new generic abortion pill, conservatives outraged
US regulators have approved an additional generic version of the abortion pill mifepristone, a normally routine move that nevertheless angered anti-abortion activists.
A number of conservative figures and anti-abortion groups decried the regulatory step, with the institution Students for Life Action calling it "a stain on the Trump presidency."
The drugmaker Evita said on its website the US Food and Drug Administration had this week approved the company's generic tablet, which is currently approved to end pregnancies up to 70 days of gestation.
The medication is used in the majority of abortions in the United States, and also routinely used for managing early miscarriage.
The FDA originally approved mifepristone in 2000, and another generic already exists.
Approvals of additional generics are typically routine.
But Marjorie Dannenfelser, president of the organization Susan B. Anthony Pro-Life America, called the approval "reckless" and "unconscionable" in a statement Thursday.
Senator Josh Hawley, a Republican from Missouri, said on X he had "lost confidence" in FDA leadership while former vice president Mike Pence posted it was "a complete betrayal of the pro-life movement that elected President Trump."
Pence also called for the dismissal of Robert F. Kennedy Jr, Trump's controversial health chief.
The ruckus comes weeks after Kennedy and FDA Commissioner Marty Makary reportedly delivered a letter to 22 Republican attorneys general saying the FDA was conducting a new review of mifepristone's safety.
Abortion rights organizations have dubbed that a blatant attempt to undermine health care access, and a coalition of attorneys general from more than a dozen Democratic-led states vowed to protect availability of the drug.
The American Medical Association has called the prescription drug "exceedingly safe and effective" and said restricting access to mifepristone would "jeopardize public health."
That take echoes the positions of many leading medical institutions.
Mifepristone, which prevents pregnancy progression, is generally used in combination with misoprostol, which empties the uterus.
J.Saleh--SF-PST